Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term dupilumab safety in adults with atopic dermatitis from prior dupilumab trials
2013-001449-15Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events incidence and rate. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2013-001449-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001449-15.